Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.
Melissa L. Abel(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Jeanny B. Aragon‐Ching(Inova Fairfax Hospital), Lisa M. Cordes(National Institutes of Health Clinical Center), Katherine Lee-Wisdom(National Institutes of Health), Amy Hankin(National Institutes of Health), Fatima Karzai(National Institutes of Health), Esther Mena(National Institutes of Health), James L. Gulley(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), William D. Figg(National Cancer Institute), Liza Lindenberg(National Cancer Institute), Clara Chen(National Institutes of Health Clinical Center), Monique Williams(National Institutes of Health), Yolanda McKinney(National Cancer Institute), Peter Choyke(National Institutes of Health)
Cited by 0
Related Papers
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
|Journal of Clinical Oncology|2014|714
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456